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The recent recognition that the conducting airways are not “sterile” and that they have 
their own dynamic microbiome, together with the rapid advances in our understanding of 
microbial biofilms and their roles in the causation of respiratory diseases (such as chronic 
bronchitis, sinusitis, and chronic otitis media), permit us to update the “vicious circle” 
hypothesis of the causation of bronchiectasis. This proposes that chronic inflammation 
driven by persistent bacterial bronchitis (PBB) causes damage to both the epithelium, 
resulting in impaired mucociliary clearance, and to the airway wall, which eventually 
manifests as bronchiectasis. The link between a “chronic bronchitis” and a persistence 
of bacterial pathogens, such as non-typable Haemophilus influenzae, was first made 
more than 100 years ago, and its probable role in the causation of bronchiectasis was 
proposed soon afterward. The recognition that the “usual suspects” are adept at forming 
biofilms and hence are able to persist and dominate the normal dynamically changing 
“healthy microbiome” of the conducting airways provides an explanation for the chronic 
colonization of the bronchi and for the associated chronic neutrophil-dominated inflam-
mation characteristic of a PBB. Understanding the complex interaction between the host 
and the microbial communities of the conducting airways in health and disease will be a 
key component in optimizing pulmonary health in the future.
Keywords: protracted bacterial bronchitis, recurrent bronchitis, bronchiectasis, chronic cough, endobronchial 
infection
iNTRODUCTiON
Our understanding of the role of bacteria in pulmonary disease is undergoing a transformation that 
will hopefully, in time, take pulmonary medicine into a new era of clarity regarding pulmonary 
health and disease. The idea that a persistent bacterial “infection” of the lower airways could be 
a cause of disease, characterized by a chronic cough, is not new. Excellent clinical descriptions 
of the disease that many now refer to as protracted or persistent bacterial bronchitis (PBB) long 
predated the recognition that bacteria might drive the disease. Physicians generally used terms 
such as chronic catarrh or chronic bronchitis (1–7), although numerous other names have also 
been used to describe the same condition including “pre-bronchiectasis,” chronic endobronchial 
infection, chronic suppurative lung disease, and indeed bronchiectasis, when used as a descriptor of 
a disease rather than a pathological appearance (8). Almost universally, it was noted that this was 
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a common condition in childhood, often commencing in infancy 
or the very early years of life, usually after an acute bronchitis 
failed to resolve. It was particularly common in the poorer sec-
tions of society. During the early years of the twentieth century, 
it was established that a number of bacterial organisms were 
commonly identified in the sputum of individuals with chronic 
pulmonary diseases, including bronchiectasis and chronic bron-
chitis (9–11). The advent of antibiotics was associated with a rapid 
reduction in both the number of children admitted to hospital 
with “bronchiectasis” (12) and the number of children being 
diagnosed with “bronchiectasis” due to causes other than cystic 
fibrosis (CF) and immunodeficiency, such that many considered 
it an orphan disease from a by-gone era, at least in developed 
countries (13). Similarly by the 1980s, chronic bronchitis in 
childhood was felt to be a very uncommon condition (14, 15). 
This, together with a focus on asthma as the dominant cause of 
chronic respiratory symptoms in childhood, led many [though 
not all (16)] to dismiss the concept of a chronic endobronchial 
infection as a cause of chronic morbidity. This position was 
reinforced by their belief that the lungs were “sterile” and that 
bacteria caused acute illnesses that fully resolved, despite both 
propositions having been shown to be false decades before.
Over recent years, there has been a revival of interest in the role 
of persistent bacterial “infection” of the lower airways, as a cause 
of chronic cough and associated morbidity. In part, this would 
appear to be due to a genuine increase in prevalence, though the 
lack of a simple diagnostic test makes it impossible to substantiate 
this clinical suspicion. In parallel, our concepts of the behavior 
of bacteria in a biological niche, such as the conducting airways, 
have changed fundamentally with the belated recognition that 
the lungs are not a uniquely sterile environment (17, 18) and a 
recognition of the importance of bacterial biofilms in persistence 
of bacterial communities (19, 20).
A “viCiOUS CiRCLe” iN THe CONTeXT 
OF A ReSPiRATORY MiCROBiOMe
The most plausible paradigm based on current knowledge is 
that a “chronic” bacterial bronchitis develops when one or more 
“pathogens” are able to establish themselves in the form of bio-
films within the conducting airways (21). In this way, they come 
to dominate a niche, which under normal conditions appears to 
contain a dynamic microbial community that is constantly being 
cleared and replenished, predominantly by micro-aspiration but 
also through inhalation (22, 23). The persistence and consequent 
dominance of the local microbial ecology of the monospecies or 
mixed populations within the biofilms drive a chronic inflamma-
tory state, which is of benefit to organisms such as non-typable 
Haemophilus influenzae (NTHi). NTHi utilizes products such as 
the DNA within neutrophil nets, for both nutritional and matrix 
building purposes, and will also benefit from the release of other 
nutrients into the local environment driven by the inflammation 
(20, 24). Moreover, the stimulated host response helps the NTHi 
compete with other potential pathogens such as Streptococcus 
pneumoniae (25) and with the normal “microbiota,” such that the 
diversity within the airways falls. Viral infections appear to not 
only enable the initiation of surface attachment and initiation of 
biofilms but also be the trigger for “exacerbations” characterized 
by the release of planktonic organisms, which will generate an 
enhanced inflammatory response (26, 27). This makes biological 
sense in that the viral infection will provide an enhanced opportu-
nity to be transferred to another potential host and permit further 
expansion within the current host resulting in an “exacerbation” 
of symptoms beyond that attributable to the natural course of the 
viral illness.
Unraveling the dynamics of microbial and host interactions 
through the life course is likely to be a dominant theme in the 
coming decades as we work toward a focus on wellness and 
disease prevention. More importantly, this understanding will 
help develop a rational approach to promoting respiratory health 
though prevention and non-antibiotic-dependent strategies to 
therapy.
iS “PBB” A DiSTiNCT DiSeASe?
A persistent endobronchial infection (PBB) is a well-recognized 
feature and indeed is the defining clinical feature of the progres-
sive pulmonary disease observed in patients with CF, primary 
ciliary dyskinesia (PCD), and agammaglobulinemia.
It has been suggested that the term PBB is used to describe a 
persistent endobronchial infection, in which a major underlying 
inherited risk factor has not been identified.1 This is somewhat of 
an arbitrary distinction but does have a degree of clinical validity 
in that it carries an expectation that the condition can be cured 
and the adverse long-term consequences prevented. As such, it 
would imply that in most cases, the development of bronchiec-
tasis is entirely preventable and, if it does develop, is likely to 
be attributable to failure of clinicians to intervene appropriately.
The use of the term “PBB,” in this sense, still implies an ongo-
ing inflammatory process driven by the persistence of “patho-
genic” bacteria, for which there would be one or more factors 
contributing to its inception. As noted above, the lungs are not 
“sterile” as previously thought. What characterizes the microbial 
communities in those with an ongoing endobronchial infection is 
dominance of the microbial community by one or more “patho-
gens,” resulting in a significant reduction in the bacterial diversity 
observed within the microbial ecology of the conducting airways. 
If PBB implies the development of this process in the absence of 
the above inherited factors, it is still incumbent on the clinician to 
not only treat the infection but to also consider whether any risk 
factors are ongoing and require addressing.
While most cases appear to be “post-infectious,” anything 
that impairs mucociliary clearance is a potential risk factor. This 
includes damage to the ciliated epithelium through recurrent 
aspiration, poorly controlled asthma, or inhaled toxins such 
as tobacco smoke. A second group is represented by structural 
issues such as tracheo- and/or bronchomalacia, as well as 
bronchial narrowing, the latter which includes narrowing due 
to mucosal swelling secondary to large left-to-right shunts (such 
1 Kantar A, Chang AB, Shields MD, Marchant JM, Grimwood K, Grigg J, et al. ERS 
Task Force Document: protracted bacterial bronchitis in children TF-2015-03. Eur 
Respir J (Forthcoming). 
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as may occur with a ventricular septal defect) and impingement 
from dilated or abnormally sited blood vessels. Relatively minor 
immune impairments such as low IgG subclasses or low MBL lev-
els also appear to be a risk factor, while acquired defects, such as 
that which develop during treatment for oncological conditions, 
are another relatively common cause. None of these inevitably 
lead to the development of PBB, in contrast to the major inherited 
conditions outlined above.
In the past, the condition was attributed to failure of an 
acute bronchitis or bronchopneumonia to resolve. Pertussis and 
measles infections were felt to be particularly likely to facilitate 
the onset of a chronic bronchitis (and in time progression to 
bronchiectasis) but accounted for a minority of cases. Both result 
in significant damage to cilia, as do significant viral infections, 
and it is likely that currently most cases of PBB develop following 
a viral lower respiratory tract infection (LRTI). NTHi, for exam-
ple, is unable to adhere to a healthy differentiated epithelium 
and hence appears to be opportunistic in the face of damage to 
the ciliated epithelium that occurs during these infections (28). 
Significant symptomatic viral LRTIs are most common in the 
first few years of life, which in part provides an explanation 
for the predilection of the condition to commence in early life, 
though structural issues and relative immune defects will also 
play a role. The impact of improved nutrition and living condi-
tions that occurred post the second world war, together with 
vaccination and the widespread use of antibiotics to “prevent 
secondary infection” (as was advocated by many in the early 
antibiotic era), led to the apparent disappearance of “chronic 
bronchitis of childhood” and bronchiectasis in the subsequent 
few decades.
In light of this, one can question whether the use of PBB as a 
discrete term can really be justified. A more pragmatic response 
may be to accept that a persistent endobronchial infection may 
be due to one of the major risk factors, which almost inevitably 
lead to the development of persistent or recurrent bacterial bron-
chitis (such as CF, PCD, and agammaglobulinemia) or one of the 
many conditions that predispose but do not inevitably lead to 
development of the condition (such as aspiration, chemotherapy, 
bronchomalacia, poorly controlled asthma, large left-to-right 
cardiac shunt, pertussis, mild impairments of innate and adaptive 
immunity, heavy exposure to tobacco smoke, persistent foreign 
body, etc.).
Throughout the past two centuries, physicians have empha-
sized the role of poverty and the related overcrowding, poor 
nutrition and “poor air” in the development of chronic bronchitis 
in children—these factors still appear to be relevant at least in 
Indigenous and less developed countries (29). However, the 
condition is far from restricted to particular social groups and in 
many children, no significant risk factors are identified (even after 
investigation), and hence, these are likely to be post-infectious, 
most commonly after a viral LRTI.
PBB AND iTS ReLATiONSHiP TO 
BRONCHieCTASiS
Bronchiectasis is not a disease but a radiological or pathological 
appearance. Lannec’s landmark publication of 1818 (1) provides 
the first description of bronchiectasis in a post-mortem sample. 
He observed that “the chronic catarrh is sometimes accompanied 
with a general or partial dilatation of the bronchia” and “the 
dilatation of the bronchia is only met with in cases of chronic 
mucous catarrh.” Thus, he correctly and robustly established the 
link between chronic bronchitis and the development of “bron-
chiectasis.” His observations long predated the identification of 
bacteria, and he speculated that the changes were due to pressure 
effects of the locally produced mucus.
The idea of a vicious cycle of inflammation, driven by 
infection, leading to damage, and thereby predisposing to 
ongoing chronic inflammation, has long formed the basis for 
our understanding of how bronchiectasis develops in most 
individuals with the condition (30–34). Of course, there are 
other mechanisms including the acute onset associated with 
post-infectious obliterative bronchiolitis in early childhood, 
severe bacterial pneumonic infections such as those due to 
PVL toxin-producing Staphylococcus aureus, and inflammatory 
conditions such as inflammatory bowel disease. The concept 
of aggressive treatment of a chronic bronchitis to prevent pro-
gression to bronchiectasis is also long standing (31, 35). In all 
publications from Lannec onward, there is clear guidance that 
complete resolution of an acute bronchitis/catarrh was necessary 
in order to prevent the establishment of a chronic bronchitis. In 
1947, Patterson and Moncrieff noted that when discussing the 
prevention of bronchiectasis, “it is important to realise a cough 
persisting in a child longer than a few weeks requires full investiga-
tion and early treatment.” (31)
Many patients will have radiological bronchiectasis and feel 
well between exacerbations. From the earliest reports, physi-
cians have observed that many patients with bronchiectasis 
were well much of the time but prone to “bronchitis” in the 
winter. Furthermore, the majority of morbidity associated with 
“bronchiectasis” appears to be directly attributable to the associ-
ated persistent or recurrent endobronchial infection, which is 
the cause of the disease (35–37). Conversely, the belief that all 
is well if the CT scan does not demonstrate bronchiectasis is 
one of the many fallacies that has bedeviled this field over the 
past 20  years and led to missed opportunities to prevent the 
development of the structural damage that eventually becomes 
apparent on high-resolution CT. The documented progression 
from “pre-bronchiectasis” to bronchiectasis based on sequential 
bronchograms was described more than half a century ago (38). 
This “progression” was not marked by any significant change in 
symptoms, and the author concluded that one could not dis-
tinguish pre-bronchiectasis and bronchiectasis on the basis of 
symptoms. It was also noted that clinical cure occurred in indi-
viduals, despite persistence of bronchiectatic changes, though 
regression and/or complete resolution of “bronchiectasis” was 
also noted, all of which reinforce the argument that bronchi-
ectasis is in itself not a “disease” (39, 40). Some have suggested 
that persistence or recurrence of chronic cough is a marker for 
having developed bronchiectasis. However, the study did not 
have data at presentation but only in a selected minority when 
symptoms persisted; thus, it is impossible to interpret these data 
given the potential for changes to resolve and for the changes 
to have been present long before referral. Clinical objective 
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evidence of bronchiectasis is useful when parents are struggling 
to take the diagnosis seriously, but the presence or absence of 
bronchiectasis has not been shown in children to clearly predict 
the amount of morbidity likely to be experienced in the short to 
medium term.
It is often forgotten that much of the pulmonary function 
impairment attributable to “bronchiectasis” is due to the oblit-
eration of small airways distal to the bronchiectatic areas (41, 
42). In large part, this is because the loss of distal branches is not 
evident when viewing the CT scans, in contrast to the obvious 
more central dilatation. The process is likely to be very similar 
with inflammation destroying tissues such as smooth muscle, 
elastic tissue, and cartilage in the walls of the larger airways, 
while the same inflammation in smaller airways results in 
obliteration of the lumen, due to the proximity of the opposite 
bronchial wall.
Bronchial wall thickening is commonly observed on CT scans 
prior to the development of overt bronchiectasis and is thought to 
be due to inflammation, though it is not yet possible to exclude the 
apparent thickening being due to increased luminal mucus. Such 
changes are commonly associated with peripheral gas trapping, 
particularly evident on expiratory films. The same appearance 
can be seen in poorly controlled asthmatics.
It has been known for decades that aggressive treatment can 
result in resolution of radiologically proven “bronchiectasis” 
changes, at least in those whose bronchiectasis is not too severe 
and in the absence of major underlying problems such as CF (16, 
40, 43, 44). Hence, the view that bronchiectasis is “irreversible,” 
which is largely derived from adult clinics, is incorrect. The radio-
logically confirmed “bronchiectasis” can resolve with appropriate 
management and pre-dates the advent of antibiotics at a time 
when therapy was driven by airway clearance/physiotherapy, 
breathing exercises, nutrition, and fresh air.
PRevALeNCe
There are no prevalence data for this condition, which is a major 
problem when trying to assess its societal importance and jus-
tify research in this area. Using bronchiectasis as a marker of 
prevalence, given the probable role of a persistent endobronchial 
infection in the causation of so many cases of bronchiectasis, it 
would appear to be more common in third world and Indigenous 
populations (13, 45–47). A 1997 review of studies reporting the 
prevalence of cough among primary school children undertaken 
in the decades after introduction of antibiotics (48) included a 
1996 study from Poland that reported prevalence of chronic 
cough of 31.9%, a 1996 study from the USA reporting 27.4% 
with a “persistent” cough, a 1995 study from the Netherlands 
reporting chronic cough in 12.6% of children, a study from Israel 
reporting chronic cough with sputum in 8.1%, a 1992 study from 
Italy giving a prevalence of cough and phlegm in 5.5%, and a 
Canadian study reporting chronic cough with phlegm in 5.3%. 
As noted above bronchiectasis, and by inference PBB, is common 
in South East Asia and Indigenous populations. There is little or 
no information regarding non-HIV- or TB-related bronchiec-
tasis in Africa, causing some to suggest that it is a rare cause of 
morbidity on the continent. An alternative explanation is that 
the ascertainment is low. A recent study from Nigeria suggested 
that 16.6% of those aged 7–14 years have a chronic productive 
cough (49).
These studies, as with most asthma epidemiological studies, 
did not generally include detailed clinical assessment, so it is 
impossible to determine how many of the symptomatic children 
had an ongoing endobronchial bacterial infection. It appears the 
vast majority with a persistent dry cough will become symptom 
free without treatment over a number of months, and among 
these conditions, infection (such as pertussis) is a significant 
contributor (50). Hence, it is likely that the figures for those 
studies reporting chronic cough with phlegm may provide a 
better guide to the prevalence of PBB. However, a proportion of 
those with a chronic productive cough is likely to have poorly 
controlled or untreated asthma. A study by Carter et  al. (51) 
found that 7.2% of 2,397 Canadians aged 11–15 years old met 
the criteria for a chronic bronchitis (similar to many studies 
reported in the review above). Of these, 47% appeared to have 
asthma on the basis of a self-reported wheeze assisted with 
video examples. This does not exclude subjects having asthma 
and a co-morbidity such as PBB, though it seems unlikely that 
this would account for all of them. Even excluding those who 
appeared to have asthma, 3.8% of the population had non-
asthma related chronic bronchitis, which makes it a significant 
cause of morbidity.
A well-designed community-based study is urgently required 
to assess current levels of symptoms and to determine with greater 
accuracy the prevalence and natural history of conditions, such 
as PBB, in childhood.
iNFORMATiON FROM STUDieS 
CONDUCTeD iN SeCONDARY CARe
A number of studies published in the past decade involving 
children referred to secondary care with respiratory symptoms, 
such as chronic cough, difficult asthma, or recurrent chest 
infections, identified bacterial bronchitis to be perhaps the 
commonest diagnosis in those with a persistent “wet” cough 
(8, 51–59). A study involving 190 young children in whom the 
diagnosis was made after referral to secondary care (60) found 
that 80% had made 5 or more visits to the doctor in the previous 
12 months and 53% had made 10 or more visits prior to referral, 
supporting the suggestion that the condition is under-recog-
nized in primary care. This is perhaps not surprising, given the 
high rates of self-resolving acute “viral” respiratory infections 
in the community, which can be linked to the drive to reduce 
inappropriate antibiotic prescribing for self-limiting infections. 
Several large studies have indicated that at most, only a very 
small proportion of acute respiratory illness fail to resolve by 
28 days, and of these, many will subsequently resolve (50, 61). 
All of this together with “opinion leaders” encouraging primary 
care physicians to focus on asthma reinforce the impression that 
acute respiratory illnesses are common but self-limiting, and 
that if symptoms are ongoing, they are probably “just another 
virus” or asthma.
There are likely to be high levels of unnecessary morbidity 
among at risk groups in the community (such as those with 
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severe cerebral palsy) that are attributable to unrecognized and 
hence untreated ongoing bacterial bronchitis. However, it is 
salutary to note that even among those referred to a second-
ary care service with a “chronic wet cough” of greater than 
3 weeks duration, more than 20% resolve without any specific 
interventions (53). It is quite possible, but far from certain, that 
many of these may have had a PBB. A small randomized trial 
of antibiotics for the treatment of children with a clinical PBB 
(62) found that there was a statistically significant difference 
in clearance of cough at 2  weeks between those treated with 
antibiotics and those not on antibiotics. However, it is of note 
that only 48% of those treated with co-amoxiclav cleared their 
cough, while 16% of those on placebo became cough free. 
Clearly, recognition that such “spontaneous” resolution can 
occur is very important in the future design of any interven-
tion study.
This ability for symptoms consistent with a chronic bronchitis 
to resolve “spontaneously” has been recognized for hundreds 
of years. A consistent report over time is that it is common for 
those with “chronic bronchitis” to become symptom free in the 
summer, and it is not uncommon to hear parents observe that 
their child’s cough resolves when on their summer holidays. 
Indeed, clinicians have been recommending that patients with 
a “chronic bronchitis” move to warm dry climates, should 
“conventional” therapy fail since at least the early nineteenth 
century.
ReSOLUTiON AND NATURAL HiSTORY
The elephant in the room in this field is: if “PBB” is a true entity 
that may sooner or later lead to the development of radiologically 
diagnosed bronchiectasis, why do most of the subjects appear to 
be pre-school children, with relatively few presenting at a later 
age? This would suggest that children who are symptomatic for 
extended periods of time are able to recover as the number of 
viral LRTI falls and their immunity develops, which is consistent 
with the observation above. Alternatively, that the symptoms 
generally become less troublesome with increasing age, again 
probably due to reduced exacerbations from viral infections and 
immunological changes, and increasing activity and possibly 
other undefined factors. There is certainly evidence for the latter 
in that follow-up of children with established bronchiectasis 
being treated in hospital in the 1950s found that symptoms and 
adverse impact on quality of life generally fell markedly through 
the second decades, and this improvement was maintained into 
the next decades (12). However, many patients now turning 
up in adult “bronchiectasis” clinics in middle age are probably 
experiencing deterioration of a condition, whose roots go back 
into childhood.
A further factor in the reduction of presentations in the 
primary school age and beyond is that the child and their family 
learn to live with it—they will report being fine despite significant 
symptoms because they are so much better than when younger. 
The lack of help following repeated presentations to doctors con-
tributes to an acceptance that nothing can be done, while many 
parents simply tune out their child’s cough as it becomes part of 
their life. The study from Seattle (51) suggests that this may be a 
major factor, given that the prevalence of chronic bronchitis was 
7.2% in 7- to 14-year olds, yet very few will have been subject to 
detailed clinical assessment.
DiAGNOSTiC CHALLeNGeS
The clinical features of the condition and the challenges in inter-
preting aspects of both the history and examination have been 
discussed elsewhere (8). At present, we do not have a simple 
non-invasive test that permits a robust diagnosis, and hence, it is 
inevitable that over- and under-diagnosis will be relatively com-
mon, as is still the case for asthma.
The so-called “definitive test” is a bronchoscopy and bron-
choalveolar lavage (BAL), but interpretation is fraught with 
difficulty.
(a) Different laboratories report BAL differently using 
“quantitative” (e.g., 3 ×  104) or qualitative (e.g., “moder-
ate growth”) methods to indicate the likely bacterial load. 
Such approaches, particularly the quantitative approach, 
were developed in the context of acute planktonic bacterial 
infections such as acute urinary tract infections or acute 
lobar pneumonia. Currently, there is no accepted approach 
to interpretation of culture data in the diagnosis of biofilm 
diseases (63). Given that a chronic endobronchial bacterial 
infection is likely to be a biofilm-dominated disease, this 
precludes the use of clear quantitative cut offs. A recent 
study which demonstrated the presence of biofilms in the 
lower airways of children with non-CF bronchiectasis also 
highlighted that the biofilms were often not present in the 
first lavage, presumably due to attachment of the biofilm to 
the epithelial surface (64).
(b) Conventional microbiology is in part a subjective area, and 
the author has long divided each BAL sample, knowing that 
commonly the same sample will produce a positive culture 
and a negative culture.
(c) Studies repeatedly report that approximately 25–30% of 
samples from children with a presumed PBB do not culture 
a “pathogen.” This may be due to the issues raised above. The 
impact of recent courses of antibiotics in suppressing bacte-
rial metabolism and proliferation is another potential factor, 
and we commonly try to have patients free of antibiotics for 
4–6 weeks before a bronchoscopy if possible. However, this 
is frequently not possible, and it is also common to culture 
“pathogens” even when apparently on antibiotics, perhaps 
attributable to increased release of planktonic organisms 
with exacerbations.
(d) Another potential explanation is that the “usual suspects” do 
not include the full range of biofilm-forming organisms that 
drive airway inflammation. The most likely culprits include 
members of the “normal oral flora” such as certain Neisseria 
species (65).
(e) As noted above, it is only recently that studies utilizing 
metagenomic sequencing have challenged the somewhat 
bizarre view that the lower airways are normally sterile. 
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However, as with many aspects of respiratory medicine, 
we are coming full circle in that studies from the early 
twentieth century have consistently found bacteria such as 
S. pneumoniae in the lungs of “healthy” individuals. A num-
ber of studies appear to have confirmed that this and other 
“pathogens” can be isolated from BAL samples obtained 
from completely well children. If, as has been suggested, this 
is due to contamination of the bronchoscope as it traverses 
the upper airways, then it would call into question all cul-
ture results, as it will be impossible to know if the sample is 
contaminated or not. In a recent small (unpublished) study 
in which a bronchoscopy was undertaken via endotracheal 
tube inserted for an orthopedic procedure in a previously 
entirely well child, two of the four BAL samples cultured 
significant quantities of S. pneumoniae and/or NTHi.
(f) The use of qualitative neutrophil counts can help interpret the 
data, but again the range of “% neutrophils” in the differential 
cell count varies enormously. In some patients, the values 
can overlap with “normal” values presumably as a conse-
quence of factors such as disease activity, recent antibiotics, 
and extent of disease across the extremely large surface area 
represented by the conduction airways. Conversely, a high 
percentage neutrophils among cells obtain by BAL may sim-
ply due to a viral infection. Infants with acute bronchiolitis, 
for example, have greatly elevated cell numbers in the BAL, 
and the vast majority of these are neutrophils with median 




The most pragmatic guide to management is that if a child with a 
recurrent endobronchial bacterial infection is coughing, there is 
ongoing inflammation and at best the airways are not recovering. 
Conversely, if the child is not coughing, the airways are probably 
undergoing repair and healing. The goal of “cure” is to reach a 
point that the child consistently recovers from viral respiratory 
infections without the use of antibiotics at the same time as other 
children.
There is little in the literature to guide treatment, other than a 
general consensus that the cough will resolve in 10–14 days in the 
vast majority of subjects when treated with high-dose antibiotics 
such co-amoxiclav 40–50  mg/kg/day. Issues such as whether 
the course should be extended to provide opportunities for the 
airways to recover and if so, should this be 4, 6, or 26 weeks, have 
not been explored at all.
The initial course of treatment is aimed at both addressing 
the morbidity and being part of the diagnostic process, with 
a clear and unequivocal cessation of coughing being taken as 
confirmatory evidence of the putative diagnosis. However, as 
noted above, the response may have been a regression to the 
mean though if the cough does not reoccur, neither parent nor 
doctor worry overly. “Coughing less” is not sufficient and may 
simply be regression to the mean. Typically the child’s wellbe-
ing improves in the first week, and the cough tends to resolve 
at around 10–14  days. Failure to respond may be because of 
incorrect putative diagnosis, poor adherence, or unidentified 
host or bacterial factors. In some who fail to respond to the 
above, the symptoms resolve with a change to therapy such as 
azithromycin, though why this should be when all the “usual” 
organisms are generally susceptible in vitro is unclear. There is 
also ongoing debate as to the role of a twice daily regime rather 
than a three times a day amoxicillin regime in some treatment 
failures. On occasions, much higher doses of amoxicillin appear 
to be required, necessitating the use of both co-amoxiclav and 
additional amoxicillin (up to 90 mg/kg/day of amoxicillin).
The use of macrolides does appear to be associated with 
increased incidence of antibiotic resistance (67).
Once the cough has resolved, it is assumed that the pathogenic 
organism has been eradicated, or at least the load of bacteria is 
greatly reduced, though it is quite likely that bacteria within 
biofilms further alter their metabolism, becoming virtually latent 
in order to deal with the antibiotic threat. A common experience 
is for symptoms to reoccur, which is not surprising, given the 
conceptual model above. Even in the absence of bronchiectasis, 
the conducting airways will be damaged from weeks, months, 
and years of neutrophilic inflammation. At the very least, the 
epithelial structure, including cilia, must recover and data from 
the literature suggest that recovery of ciliated epithelium after 
a brief acute viral infection (which is characterized by intense 
neutrophilic inflammation) can take weeks to months to fully 
recover (68).
Hence, it is perhaps not surprising that a bacterial bronchitis 
is frequently re-established, given that the major predisposing 
factor for a PBB is impaired mucocillary clearance, that the upper 
airways of children are often colonized by potential respiratory 
“pathogens,” and that oro-pharyngeal content is likely to be 
regularly aspirated. Given this conceptual model, many clini-
cians will continue the antibiotics for 6–8 weeks after resolution 
of the cough to permit repair of the airway structure, though 
some will stop at 2 weeks, while others report leaving patients on 
for 6 months or through the whole of the first winter following 
diagnosis. This model suggests that when the children are well 
and not coughing, they are likely to be repairing their airways. 
However, if they are coughing (other than the transient coughing 
with a viral infection), this signifies ongoing inflammation and 
the patients are failing to repair their airways but are also more 
likely to be contributing to further damage, which may progress 
to bronchiectasis evident on a CT scan or bronchogram. As with 
much in this area, further studies are required to confirm that this 
is indeed the most effective and pragmatic approach.
The idea that a long course of antibiotics might be required to 
treat respiratory patients other than those with CF, PCD, or non-
CF bronchiectasis has been a challenge for many pulmonologists, 
though the use of “prophylactic” (i.e., long-term) antibiotics is 
widely practised by immunologists looking after children with 
“recurrent” infections, who do not have major immune defects.
There is no evidence base for any of these approaches, and 
research is urgently required. The challenge in designing studies 
is that the disease, as with asthma, has a spectrum of severity, from 
those in whom the condition persists for some weeks and months 
but resolves spontaneously to those in whom failure to make the 
diagnosis has resulted in established bronchiectasis. Anecdotally, 
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in the absence of an identified major risk factor, the longer the 
symptoms have persisted, the longer it takes to clear the condi-
tion but this is far from reliable. This is presumably influenced 
by the extent of disease and risk factors such as relatively minor 
immunodeficiency in either the innate or humoral systems, 
overcrowding, frequencies of viral infections, and exposure to 
respiratory bacterial pathogens (such as in nurseries), as well as 
other factors that may play a role such as exposure to cigarette 
or other smoke. Adherence is of course likely to be a factor in 
some, though it is surprising how infrequent this appears to be 
the case for bacterial bronchitis compared to asthma. This may be 
because the improvement in quality of life for the individual and 
the family is such that parents are motivated and partly because, 
if explained clearly, the families are offered the potential of a cure 
rather than simply controlling a condition.
If longer courses are used, there must be a transition from 
requiring antibiotics to maintain health to a position where the 
condition is cured and the child can experience a viral respiratory 
infection without reoccurrence. This again varies from child to 
child with strategies being used including commencing a 2-week 
course at the onset of colds, then moving to waiting for 5–10 days 
to determine whether symptoms will resolve spontaneously, as 
individuals progress from persistent symptoms to cure.
The role of physiotherapy is also unclear. While the saying 
“it is better out than in” is undoubtedly as true in persistent 
bacterial infections as in the surgical drainage of an abscess, 
PBB will resolve in many with antibiotics alone. If the condition 
reoccurs, physiotherapy is likely (but not proven) to be helpful, as 
are strategies to try and minimize airway collapse in those with 
significant malacia, such as bubble positive expiratory pressure.
FUTURe
Recommending when to intervene with antibiotics in order to 
prevent the establishment of a bacterial bronchitis is challenging. 
It is important not to develop a position of treating all apparent 
viral infections in order to prevent the development of a chronic 
bronchitis (as was recommended in the early days of antibiotics), 
but it is equally clear that eradication is easier before the condi-
tion becomes chronic. With a median duration of approximately 
6 days for most respiratory viruses being reported in all age groups 
and the vast majority of episodes resolving before 21 days, it may 
be reasonable to restrict antibiotics to those who have an ongoing 
wet cough at 3 weeks. Again, this is an entirely evidence-free zone 
and even this may mean the benefits to a few may be outweighed 
by the societal impact of antibiotics. Against this is the antibiotic 
use required to cure an individual of the condition, particularly if 
they ultimately progress to significant airway damage.
Developing rapid non-invasive testing to identify ongoing 
inflammation typical of a bacterial bronchitis or markers of per-
sistence (for example, quorum-sensing molecules) using some 
of the newer “omics” technologies such as metabolomics, might 
ultimately permit the rational use of antibiotics for respiratory 
symptoms.
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